Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of idebenone tablets for visual impairment in Leber hereditary optic neuropathy
CTR20220888Phase 3Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of idebenone in Leber hereditary optic neuropathy (LHON), sponsored by Qilu Pharmaceutical. Started Jul 2022; status: completed.
02
Drugs
idebenone
03
Conditions
Leber hereditary optic neuropathy (LHON)
Beyond the preview
Go deeper on CTR20220888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220888.